DATE & LOCATION
May 2, 2013 | The Broad Institute | Cambridge, MA
Funding biotech companies has probably never been harder than it is today. The old model of the highly capitalized fully-integrated bricks and mortar biotech with a concept that raises millions dollars in venture funding on its way to going public is a thing of the past.
VC's have less capital, capital is more expensive, M&A and option deals are often negotiated before investors will invest and IPO's are no longer the likely exit.
Today, angels are more active and are investing in therapeutic companies, VC's are looking for lower risk bigger opportunities, and big pharma are playing a larger role in exits and early stage fundings.
Join us on May 2, 2013 at The Broad Institute where you will hear from our panel of experts on the latest ideas on how YOU should set up, manage, partner and fund a new biotech venture today to best ensure that"if you build it, they will come."
5:30-6:30pm: Cocktails, Hors d'oeuvres and Networking
6:30-8:00pm: Panel Discussion
Chief Operating Officer | Accellient Partners
Chief Financial Officer | Synchroneuron Inc.
Member | Boston Harbor Angels
Therapeutic Angel Investor
Co-Chair of Cherrystone Angels
Partner, Third Rock Ventures
Partner, SR One Ltd
Strategic Pharmacuetical Executive
Mark Day, PhD
Global Lead for CNS Search and Evaluation in the Strategic Transactions Group at Bristol Myers Squibb
Serial Founder/CEO, Visiting Scholar at Wyss Institute for Biologically Inspired Engineering, and Principal at Cold Spring Venture Advisors